stonks4u
Sign up free
CCCC logo

CCCC C4 Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$4.24
+0.16 (+3.92%)

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader…

Market Cap: $468.80Mwww.c4therapeutics.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
80
Aug 11Aug 11

Quote

Day Range
$3.90 – $4.32
52-Week Range
$1.69 – $5.17
Volume
$3.40M
Market Cap
$468.80M
50-Day Avg
$3.90
200-Day Avg
$2.93
Prev Close
$4.08
Open
$4.04

Valuation & Ratios

P/E Ratio
-1.50
EPS
$-1.27
P/B Ratio
0.62
P/S Ratio
4.40
Debt/Equity
0.23
Current Ratio
7.81
Dividend Yield
+0.0%
Gross Margin
+77.8%

Returns & Efficiency

Return on Equity
-40.9%
Return on Assets
-29.2%
FCF Yield
-62.7%
EV/EBITDA
-1.40

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$35.95M$-104.99M$-1.27
2024$35.58M$-105.32M$-1.52
2023$20.76M$-132.49M$-2.67
2022$31.10M$-128.18M$-2.62
2021$45.78M$-83.89M$-1.82

Social Signal Score

30
5d
30
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1

Earnings

Thu, Nov 5(in 3 months)

Consensus estimate $-0.21 per share

5of 7 quarters beat consensus

Typical surprise +20.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Tue, Aug 11$-0.18 vs $-0.23beat
  • Tue, May 12$-0.20 vs $-0.25beat
  • Thu, Feb 26$-0.18 vs $-0.31beat
  • Thu, Nov 6$-0.44 vs $-0.41miss
  • Thu, Aug 7$-0.37 vs $-0.38beat
  • Tue, May 6$-0.37 vs $-0.48beat

Estimates and results for CCCC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

CCCChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newszacks.com·4d ago·Negative

    C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.37 per share a year ago.

    View source ↗